<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d169" origId="Cerivastatin"><sentence id="DrugDDI.d169.s0" origId="s0" text="Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle."><entity id="DrugDDI.d169.s0.e0" origId="s0.p0" charOffset="0-17" type="drug" text="Immunosuppressive"/><entity id="DrugDDI.d169.s0.e1" origId="s0.p1" charOffset="37-48" type="drug" text="Derivatives"/><entity id="DrugDDI.d169.s0.e2" origId="s0.p2" charOffset="50-56" type="drug" text="Niacin"/><entity id="DrugDDI.d169.s0.e3" origId="s0.p4" charOffset="58-72" type="drug" text="Nicotinic Acid"/><entity id="DrugDDI.d169.s0.e4" origId="s0.p5" charOffset="74-86" type="drug" text="Erythromycin"/><entity id="DrugDDI.d169.s0.e5" origId="s0.p6" charOffset="88-105" type="drug" text="Azole Antifungals"/><pair id="DrugDDI.d169.s0.p0" e1="DrugDDI.d169.s0.e0" e2="DrugDDI.d169.s0.e1" interaction="?"/><pair id="DrugDDI.d169.s0.p1" e1="DrugDDI.d169.s0.e0" e2="DrugDDI.d169.s0.e2" interaction="?"/><pair id="DrugDDI.d169.s0.p2" e1="DrugDDI.d169.s0.e0" e2="DrugDDI.d169.s0.e3" interaction="?"/><pair id="DrugDDI.d169.s0.p3" e1="DrugDDI.d169.s0.e0" e2="DrugDDI.d169.s0.e4" interaction="?"/><pair id="DrugDDI.d169.s0.p4" e1="DrugDDI.d169.s0.e0" e2="DrugDDI.d169.s0.e5" interaction="?"/><pair id="DrugDDI.d169.s0.p5" e1="DrugDDI.d169.s0.e1" e2="DrugDDI.d169.s0.e2" interaction="?"/><pair id="DrugDDI.d169.s0.p6" e1="DrugDDI.d169.s0.e1" e2="DrugDDI.d169.s0.e3" interaction="?"/><pair id="DrugDDI.d169.s0.p7" e1="DrugDDI.d169.s0.e1" e2="DrugDDI.d169.s0.e4" interaction="?"/><pair id="DrugDDI.d169.s0.p8" e1="DrugDDI.d169.s0.e1" e2="DrugDDI.d169.s0.e5" interaction="?"/><pair id="DrugDDI.d169.s0.p9" e1="DrugDDI.d169.s0.e2" e2="DrugDDI.d169.s0.e3" interaction="?"/><pair id="DrugDDI.d169.s0.p10" e1="DrugDDI.d169.s0.e2" e2="DrugDDI.d169.s0.e4" interaction="?"/><pair id="DrugDDI.d169.s0.p11" e1="DrugDDI.d169.s0.e2" e2="DrugDDI.d169.s0.e5" interaction="?"/><pair id="DrugDDI.d169.s0.p12" e1="DrugDDI.d169.s0.e3" e2="DrugDDI.d169.s0.e4" interaction="?"/><pair id="DrugDDI.d169.s0.p13" e1="DrugDDI.d169.s0.e3" e2="DrugDDI.d169.s0.e5" interaction="?"/><pair id="DrugDDI.d169.s0.p14" e1="DrugDDI.d169.s0.e4" e2="DrugDDI.d169.s0.e5" interaction="?"/></sentence><sentence id="DrugDDI.d169.s1" origId="s1" text="ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid."><entity id="DrugDDI.d169.s1.e0" origId="s1.p9" charOffset="0-7" type="drug" text="ANTACID"/><entity id="DrugDDI.d169.s1.e1" origId="s1.p11" charOffset="9-38" type="drug" text="Magnesium-Aluminum Hydroxide"/><entity id="DrugDDI.d169.s1.e2" origId="s1.p14" charOffset="40-52" type="drug" text="Cerivastatin"/><entity id="DrugDDI.d169.s1.e3" origId="s1.p19" charOffset="117-124" type="drug" text="antacid"/><pair id="DrugDDI.d169.s1.p0" e1="DrugDDI.d169.s1.e0" e2="DrugDDI.d169.s1.e1" interaction="?"/><pair id="DrugDDI.d169.s1.p1" e1="DrugDDI.d169.s1.e0" e2="DrugDDI.d169.s1.e2" interaction="?"/><pair id="DrugDDI.d169.s1.p2" e1="DrugDDI.d169.s1.e0" e2="DrugDDI.d169.s1.e3" interaction="?"/><pair id="DrugDDI.d169.s1.p3" e1="DrugDDI.d169.s1.e1" e2="DrugDDI.d169.s1.e2" interaction="?"/><pair id="DrugDDI.d169.s1.p4" e1="DrugDDI.d169.s1.e1" e2="DrugDDI.d169.s1.e3" interaction="?"/><pair id="DrugDDI.d169.s1.p5" e1="DrugDDI.d169.s1.e2" e2="DrugDDI.d169.s1.e3" interaction="?"/></sentence><sentence id="DrugDDI.d169.s2" origId="s2" text="CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine."><entity id="DrugDDI.d169.s2.e0" origId="s2.p22" charOffset="12-24" type="drug" text="Cerivastatin"/><entity id="DrugDDI.d169.s2.e1" origId="s2.p27" charOffset="89-99" type="drug" text="cimetidine"/><pair id="DrugDDI.d169.s2.p0" e1="DrugDDI.d169.s2.e0" e2="DrugDDI.d169.s2.e1" interaction="?"/></sentence><sentence id="DrugDDI.d169.s3" origId="s3" text="CHOLESTYRAMINE: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies."><entity id="DrugDDI.d169.s3.e0" origId="s3.p28" charOffset="0-14" type="drug" text="CHOLESTYRAMINE"/><entity id="DrugDDI.d169.s3.e1" origId="s3.p31" charOffset="37-64" type="drug" text="bile-acidsequestering agent"/><entity id="DrugDDI.d169.s3.e2" origId="s3.p33" charOffset="107-126" type="drug" text="cerivastatin sodium"/><pair id="DrugDDI.d169.s3.p0" e1="DrugDDI.d169.s3.e0" e2="DrugDDI.d169.s3.e1" interaction="?"/><pair id="DrugDDI.d169.s3.p1" e1="DrugDDI.d169.s3.e0" e2="DrugDDI.d169.s3.e2" interaction="?"/><pair id="DrugDDI.d169.s3.p2" e1="DrugDDI.d169.s3.e1" e2="DrugDDI.d169.s3.e2" interaction="?"/></sentence><sentence id="DrugDDI.d169.s4" origId="s4" text="In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone."><entity id="DrugDDI.d169.s4.e0" origId="s4.p42" charOffset="57-76" type="drug" text="cerivastatin sodium"/><entity id="DrugDDI.d169.s4.e1" origId="s4.p44" charOffset="86-100" type="drug" text="cholestyramine"/><entity id="DrugDDI.d169.s4.e2" origId="s4.p55" charOffset="189-208" type="drug" text="cerivastatin sodium"/><pair id="DrugDDI.d169.s4.p0" e1="DrugDDI.d169.s4.e0" e2="DrugDDI.d169.s4.e1" interaction="?"/><pair id="DrugDDI.d169.s4.p1" e1="DrugDDI.d169.s4.e0" e2="DrugDDI.d169.s4.e2" interaction="?"/><pair id="DrugDDI.d169.s4.p2" e1="DrugDDI.d169.s4.e1" e2="DrugDDI.d169.s4.e2" interaction="?"/></sentence><sentence id="DrugDDI.d169.s5" origId="s5" text="However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone."><entity id="DrugDDI.d169.s5.e0" origId="s5.p59" charOffset="53-68" type="drug" text="cholestyramine"/><entity id="DrugDDI.d169.s5.e1" origId="s5.p62" charOffset="110-129" type="drug" text="cerivastatin sodium"/><entity id="DrugDDI.d169.s5.e2" origId="s5.p66" charOffset="210-222" type="drug" text="cerivastatin"/><entity id="DrugDDI.d169.s5.e3" origId="s5.p75" charOffset="304-323" type="drug" text="cerivastatin sodium"/><pair id="DrugDDI.d169.s5.p0" e1="DrugDDI.d169.s5.e0" e2="DrugDDI.d169.s5.e1" interaction="?"/><pair id="DrugDDI.d169.s5.p1" e1="DrugDDI.d169.s5.e0" e2="DrugDDI.d169.s5.e2" interaction="?"/><pair id="DrugDDI.d169.s5.p2" e1="DrugDDI.d169.s5.e0" e2="DrugDDI.d169.s5.e3" interaction="?"/><pair id="DrugDDI.d169.s5.p3" e1="DrugDDI.d169.s5.e1" e2="DrugDDI.d169.s5.e2" interaction="?"/><pair id="DrugDDI.d169.s5.p4" e1="DrugDDI.d169.s5.e1" e2="DrugDDI.d169.s5.e3" interaction="?"/><pair id="DrugDDI.d169.s5.p5" e1="DrugDDI.d169.s5.e2" e2="DrugDDI.d169.s5.e3" interaction="?"/></sentence><sentence id="DrugDDI.d169.s6" origId="s6" text="Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium."><entity id="DrugDDI.d169.s6.e0" origId="s6.p82" charOffset="58-77" type="drug" text="cerivastatin sodium"/><entity id="DrugDDI.d169.s6.e1" origId="s6.p86" charOffset="99-113" type="drug" text="cholestyramine"/><entity id="DrugDDI.d169.s6.e2" origId="s6.p94" charOffset="213-232" type="drug" text="cerivastatin sodium"/><pair id="DrugDDI.d169.s6.p0" e1="DrugDDI.d169.s6.e0" e2="DrugDDI.d169.s6.e1" interaction="?"/><pair id="DrugDDI.d169.s6.p1" e1="DrugDDI.d169.s6.e0" e2="DrugDDI.d169.s6.e2" interaction="?"/><pair id="DrugDDI.d169.s6.p2" e1="DrugDDI.d169.s6.e1" e2="DrugDDI.d169.s6.e2" interaction="?"/></sentence><sentence id="DrugDDI.d169.s7" origId="s7" text="DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium."><entity id="DrugDDI.d169.s7.e0" origId="s7.p95" charOffset="0-7" type="drug" text="DIGOXIN"/><entity id="DrugDDI.d169.s7.e1" origId="s7.p99" charOffset="35-42" type="drug" text="digoxin"/><entity id="DrugDDI.d169.s7.e2" origId="s7.p105" charOffset="118-137" type="drug" text="cerivastatin sodium"/><pair id="DrugDDI.d169.s7.p0" e1="DrugDDI.d169.s7.e0" e2="DrugDDI.d169.s7.e1" interaction="?"/><pair id="DrugDDI.d169.s7.p1" e1="DrugDDI.d169.s7.e0" e2="DrugDDI.d169.s7.e2" interaction="?"/><pair id="DrugDDI.d169.s7.p2" e1="DrugDDI.d169.s7.e1" e2="DrugDDI.d169.s7.e2" interaction="?"/></sentence><sentence id="DrugDDI.d169.s8" origId="s8" text="Cerivastatin plasma concentrations were also not affected by co-administration of digoxin."><entity id="DrugDDI.d169.s8.e0" origId="s8.p106" charOffset="0-12" type="drug" text="Cerivastatin"/><entity id="DrugDDI.d169.s8.e1" origId="s8.p112" charOffset="82-89" type="drug" text="digoxin"/><pair id="DrugDDI.d169.s8.p0" e1="DrugDDI.d169.s8.e0" e2="DrugDDI.d169.s8.e1" interaction="?"/></sentence><sentence id="DrugDDI.d169.s9" origId="s9" text="WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo."><entity id="DrugDDI.d169.s9.e0" origId="s9.p113" charOffset="0-8" type="drug" text="WARFARIN"/><entity id="DrugDDI.d169.s9.e1" origId="s9.p116" charOffset="32-40" type="drug" text="warfarin"/><entity id="DrugDDI.d169.s9.e2" origId="s9.p118" charOffset="45-57" type="drug" text="cerivastatin"/><entity id="DrugDDI.d169.s9.e3" origId="s9.p127" charOffset="142-152" type="drug" text="factor VII"/><entity id="DrugDDI.d169.s9.e4" origId="s9.p131" charOffset="191-199" type="drug" text="warfarin"/><pair id="DrugDDI.d169.s9.p0" e1="DrugDDI.d169.s9.e0" e2="DrugDDI.d169.s9.e1" interaction="?"/><pair id="DrugDDI.d169.s9.p1" e1="DrugDDI.d169.s9.e0" e2="DrugDDI.d169.s9.e2" interaction="?"/><pair id="DrugDDI.d169.s9.p2" e1="DrugDDI.d169.s9.e0" e2="DrugDDI.d169.s9.e3" interaction="?"/><pair id="DrugDDI.d169.s9.p3" e1="DrugDDI.d169.s9.e0" e2="DrugDDI.d169.s9.e4" interaction="?"/><pair id="DrugDDI.d169.s9.p4" e1="DrugDDI.d169.s9.e1" e2="DrugDDI.d169.s9.e2" interaction="?"/><pair id="DrugDDI.d169.s9.p5" e1="DrugDDI.d169.s9.e1" e2="DrugDDI.d169.s9.e3" interaction="?"/><pair id="DrugDDI.d169.s9.p6" e1="DrugDDI.d169.s9.e1" e2="DrugDDI.d169.s9.e4" interaction="?"/><pair id="DrugDDI.d169.s9.p7" e1="DrugDDI.d169.s9.e2" e2="DrugDDI.d169.s9.e3" interaction="?"/><pair id="DrugDDI.d169.s9.p8" e1="DrugDDI.d169.s9.e2" e2="DrugDDI.d169.s9.e4" interaction="?"/><pair id="DrugDDI.d169.s9.p9" e1="DrugDDI.d169.s9.e3" e2="DrugDDI.d169.s9.e4" interaction="?"/></sentence><sentence id="DrugDDI.d169.s10" origId="s10" text="The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium."><entity id="DrugDDI.d169.s10.e0" origId="s10.p147" charOffset="52-60" type="drug" text="warfarin"/><entity id="DrugDDI.d169.s10.e1" origId="s10.p151" charOffset="108-127" type="drug" text="cerivastatin sodium"/><pair id="DrugDDI.d169.s10.p0" e1="DrugDDI.d169.s10.e0" e2="DrugDDI.d169.s10.e1" interaction="?"/></sentence><sentence id="DrugDDI.d169.s11" origId="s11" text="Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium."><entity id="DrugDDI.d169.s11.e0" origId="s11.p153" charOffset="21-29" type="drug" text="warfarin"/><entity id="DrugDDI.d169.s11.e1" origId="s11.p155" charOffset="34-46" type="drug" text="cerivastatin"/><entity id="DrugDDI.d169.s11.e2" origId="s11.p160" charOffset="85-104" type="drug" text="cerivastatin sodium"/><pair id="DrugDDI.d169.s11.p0" e1="DrugDDI.d169.s11.e0" e2="DrugDDI.d169.s11.e1" interaction="?"/><pair id="DrugDDI.d169.s11.p1" e1="DrugDDI.d169.s11.e0" e2="DrugDDI.d169.s11.e2" interaction="?"/><pair id="DrugDDI.d169.s11.p2" e1="DrugDDI.d169.s11.e1" e2="DrugDDI.d169.s11.e2" interaction="?"/></sentence><sentence id="DrugDDI.d169.s12" origId="s12" text="ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4."><entity id="DrugDDI.d169.s12.e0" origId="s12.p161" charOffset="0-12" type="drug" text="ERYTHROMYCIN"/><entity id="DrugDDI.d169.s12.e1" origId="s12.p164" charOffset="61-73" type="drug" text="cerivastatin"/><entity id="DrugDDI.d169.s12.e2" origId="s12.p174" charOffset="176-188" type="drug" text="erythromycin"/><entity id="DrugDDI.d169.s12.e3" origId="s12.p176" charOffset="211-230" type="drug" text="cytochrome P450 3A4"/><pair id="DrugDDI.d169.s12.p0" e1="DrugDDI.d169.s12.e0" e2="DrugDDI.d169.s12.e1" interaction="?"/><pair id="DrugDDI.d169.s12.p1" e1="DrugDDI.d169.s12.e0" e2="DrugDDI.d169.s12.e2" interaction="?"/><pair id="DrugDDI.d169.s12.p2" e1="DrugDDI.d169.s12.e0" e2="DrugDDI.d169.s12.e3" interaction="?"/><pair id="DrugDDI.d169.s12.p3" e1="DrugDDI.d169.s12.e1" e2="DrugDDI.d169.s12.e2" interaction="?"/><pair id="DrugDDI.d169.s12.p4" e1="DrugDDI.d169.s12.e1" e2="DrugDDI.d169.s12.e3" interaction="?"/><pair id="DrugDDI.d169.s12.p5" e1="DrugDDI.d169.s12.e2" e2="DrugDDI.d169.s12.e3" interaction="?"/></sentence><sentence id="DrugDDI.d169.s13" origId="s13" text="OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions."><entity id="DrugDDI.d169.s13.e0" origId="s13.p186" charOffset="106-125" type="drug" text="cerivastatin sodium"/><entity id="DrugDDI.d169.s13.e1" origId="s13.p190" charOffset="154-184" type="drug" text="angiotensin- converting enzyme"/><entity id="DrugDDI.d169.s13.e2" origId="s13.p196" charOffset="217-241" type="drug" text="calcium-channel blockers"/><entity id="DrugDDI.d169.s13.e3" origId="s13.p197" charOffset="243-252" type="drug" text="diuretics"/><entity id="DrugDDI.d169.s13.e4" origId="s13.p199" charOffset="258-294" type="drug" text="nonsteroidal anti-inflammatory drugs"/><entity id="DrugDDI.d169.s13.e5" origId="s13.p201" charOffset="296-302" type="drug" text="NSAIDs"/><pair id="DrugDDI.d169.s13.p0" e1="DrugDDI.d169.s13.e0" e2="DrugDDI.d169.s13.e1" interaction="?"/><pair id="DrugDDI.d169.s13.p1" e1="DrugDDI.d169.s13.e0" e2="DrugDDI.d169.s13.e2" interaction="?"/><pair id="DrugDDI.d169.s13.p2" e1="DrugDDI.d169.s13.e0" e2="DrugDDI.d169.s13.e3" interaction="?"/><pair id="DrugDDI.d169.s13.p3" e1="DrugDDI.d169.s13.e0" e2="DrugDDI.d169.s13.e4" interaction="?"/><pair id="DrugDDI.d169.s13.p4" e1="DrugDDI.d169.s13.e0" e2="DrugDDI.d169.s13.e5" interaction="?"/><pair id="DrugDDI.d169.s13.p5" e1="DrugDDI.d169.s13.e1" e2="DrugDDI.d169.s13.e2" interaction="?"/><pair id="DrugDDI.d169.s13.p6" e1="DrugDDI.d169.s13.e1" e2="DrugDDI.d169.s13.e3" interaction="?"/><pair id="DrugDDI.d169.s13.p7" e1="DrugDDI.d169.s13.e1" e2="DrugDDI.d169.s13.e4" interaction="?"/><pair id="DrugDDI.d169.s13.p8" e1="DrugDDI.d169.s13.e1" e2="DrugDDI.d169.s13.e5" interaction="?"/><pair id="DrugDDI.d169.s13.p9" e1="DrugDDI.d169.s13.e2" e2="DrugDDI.d169.s13.e3" interaction="?"/><pair id="DrugDDI.d169.s13.p10" e1="DrugDDI.d169.s13.e2" e2="DrugDDI.d169.s13.e4" interaction="?"/><pair id="DrugDDI.d169.s13.p11" e1="DrugDDI.d169.s13.e2" e2="DrugDDI.d169.s13.e5" interaction="?"/><pair id="DrugDDI.d169.s13.p12" e1="DrugDDI.d169.s13.e3" e2="DrugDDI.d169.s13.e4" interaction="?"/><pair id="DrugDDI.d169.s13.p13" e1="DrugDDI.d169.s13.e3" e2="DrugDDI.d169.s13.e5" interaction="?"/><pair id="DrugDDI.d169.s13.p14" e1="DrugDDI.d169.s13.e4" e2="DrugDDI.d169.s13.e5" interaction="?"/></sentence></document>